Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism



Status:Completed
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:June 2016
End Date:August 2016

Use our guide to learn which trials are right for you!

An Open-Label Study to Evaluate the Safety of Testosterone Enanthate After Two Single-Dose Injections Via QuickShot® Testosterone by Intended Users and QuickShot™ Summative Usability Study

Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single
dose via QuickShot® Testosterone (QST) when administered by intended users in a usability
study.

Intended users are patients as well as patient caregivers, such as family members or friends
who are able to assist the patient to administer the medication (i.e. lay users). One user
group of approximately 15 patients will have their dose administered by a qualified
healthcare professional (HCP).

Inclusion Criteria

Each patient must meet all of the following criteria at screening to participate in the
study:

1. The patient is 18 years of age or older;

2. The patient speaks, reads, and understands the English language at a sixth grade
reading level or higher;

3. The patient is willing to have photographs taken and/or be video recorded while he
completes study tasks, which will be de-identified prior to any potential use of the
image(s) for scientific or educational purposes;

4. The patient has sufficient availability to participate in the study and to comply with
the study schedule;

5. The patient has his own transportation to and from the study site;

6. The patient demonstrates the ability to understand and the willingness to follow all
study instructions; and

7. The patient has read, stated he understands, and has signed the Informed Consent Form
(ICF).

8. The patient has been diagnosed with hypogonadism;

9. The patient is a male;

10. The patient has a documented history of hypogonadism. Diagnosis must include
documentation of consistent signs and symptoms of androgen deficiency;

11. Patients in good health as determined by the Investigator and based on medical
history, physical examination, vital signs, electrocardiogram (ECG), and clinical
laboratory tests;

12. All male patients must practice effective contraception during the study and for 30
days after receiving the last dose of study drug. Acceptable methods of birth control
include condom with spermicide, vasectomy, or monogamous relations with a female
partner who is of non child-bearing potential (post-menopausal, surgical, or
congenital sterility) or is of child bearing potential and practicing a reliable
method of contraception (hormonal contraception, double barrier methods with
spermicide, or intrauterine device); and

13. Patients must have the ability to provide written informed consent and comply with all
study requirements and restrictions including the study visit schedule.

Exclusion Criteria

Patients will be excluded from participation in the study if any of the following criteria
apply:

1. Failure to meet 1 or more Inclusion Criterion;

2. The patient has participated in interviews, focus groups, or studies for any medical
products or therapies within the past 3 months or in a prior QST auto-injector
usability study, clinical trial, and/or has previous exposure to the investigational
device;

3. The patient or someone he lives with works or has worked for a Marketing/Market
Research Company, pharmaceutical or medical device company, a manufacturer,
distributor, or wholesaler of non-prescription drug products, or a government health
agency;

4. Individuals who have had an allergic reaction or idiosyncratic reaction to sesame
seeds, sesame products, and/or sesame oil;

5. History of food anaphylaxis;

6. History of intolerance, allergy, or idiosyncratic reaction to testosterone products;

7. Unstable psychiatric illnesses;

8. Lifetime history of psychosis, suicidal behavior, bipolar disorder, or personality
disorder; active suicidal ideation within 6 months prior to screening; or inadequately
treated depression. Note: Patients with depression who have been adequately treated
and with stable response for 3 months may be admitted into the study at the
Investigator's discretion;

9. Body mass index 40 kg/m2;

10. Hematocrit 52% at Initial Screening Visit;

11. Individual history or current evidence of breast or prostate cancer;

12. Other malignancy diagnosed or treated within 5 years of the date of Initial Screening
Visit with the exception of non-melanoma carcinoma of the skin;

13. Elevated prostate-specific antigen (PSA) for age. Prostate-specific antigen 2.5 ng/mL
in men 18 to 60 years old and 4 ng/mL in men 61 years and older is exclusionary;

14. Presence of prostate nodule or induration upon digital rectal exam;

15. Obstructive uropathy of prostatic origin and of a severity that, in the opinion of the
Investigator, contraindicates the use of testosterone;

16. Patients with poorly controlled diabetes. Patients on a stable dose and regimen of
anti diabetic medications for a minimum of 4 weeks, and who have a hemoglobin A1c
level of 7.5% may participate in the study;

17. Patients with New York Heart Association Class III or IV congestive heart failure;

18. Within 6 months of the Initial Screening Visit, have had myocardial infarction,
unstable angina leading to hospitalization, percutaneous coronary intervention,
coronary artery bypass graft, uncontrolled cardiac arrhythmia, stroke transient
ischemia attack, carotid revascularization, endovascular procedure, or surgical
intervention for peripheral vascular disease;

19. History of, or current treatment for, thromboembolic disease or current use of anti
thromboembolic medications. Use of low-dose aspirin is permitted for routine
cardioprophylaxis;

20. Patients intermittently taking adrenocorticotropic hormone, oral, or depot
corticosteroids (ongoing regimens required for panhypopituitarism or adrenal failure
are permitted);

21. Untreated sleep apnea;

22. Historical or current evidence of any clinically significant disease or disorder that,
in the judgment of the Investigator, may cause participation in this study to be
detrimental to the patient or which may influence the results of the study. This
includes cardiovascular, renal, hepatic, hematological, endocrine, gastrointestinal,
or pulmonary disease;

23. Positive serology for human immunodeficiency virus antibodies, hepatitis B surface
antigen, or hepatitis C virus antibody at the Initial Screening Visit;

24. Current evidence of alcohol or drug abuse. A positive drug screen is exclusionary
without documentation of a current prescription and medical condition requiring
treatment with the drug for which the screen is positive. Exception:
tetrahydrocannabinol is allowed in states where recreational use of marijuana is
legal;

25. Any skin condition that could confound injection site assessments (eg,
dermatographism, urticaria, or atopic dermatitis). Tattoos, scarring, or psoriasis of
the injection site is prohibited;

26. Administration of any other investigational compound within 1 month prior to Initial
Screening Visit or 5 half-lives of the investigational product (whichever is longer);

27. Patients considering or scheduled to undergo any major surgery or dental procedure
anticipated to be associated with significant blood loss (500 mL) during the study;

28. Systolic blood pressure (SBP) 140 mmHg and/or diastolic blood pressure (DBP) 90 mmHg
at the Initial Screening Visit. Patients with treated hypertension and SBP 140 and/or
DBP 90 mmHg at the Initial Screening Visit must be on a stable dose of
antihypertensive medication for at least 14 days at Day -1 (Baseline Visit) and plan
to remain on the same dose throughout the duration of the study; or

29. Unable to understand verbal or written English or any other language in which a
certified translation of the informed consent is available.
We found this trial at
3
sites
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials